Bionomics Prepares BNC210 for Start of Phase 2 Acute Treatment of Social Anxiety Disorder Trial
- Written by PR Newswire
- Rapid oral absorption of BNC210 novel tablet formulation potentially well-suited for acute treatment of anxiety in patients with Social Anxiety Disorder
- Phase 2 clinical trial on target to start by end of 2021 and expected to read out topline data by end of 2022
ADELAIDE, Australia, Sept. 20, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO,...